Stable isotope‐assisted metabolomics in cancer research

Stable Isotopes are nontoxic, naturally occurring elemental surrogates that are fully compatible with live organisms, including humans in a clinical setting. The ability to enrich common compounds with rare isotopes such as carbon (13C) and nitrogen (15N) is the only practical means by which metabolic pathways can be traced, performed by following the fate of individual atoms from the source molecules to products via metabolic transformation. Changes in regulation of pathways are therefore captured by this approach, which leads to deeper understanding of fundamental biochemistry of cancer compared with non‐cancerous cells, which can lead to new diagnostic tools. © 2008 IUBMB IUBMB Life, 60(2): 124–129, 2008

[1]  R. Cataneo,et al.  Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study , 1999, The Lancet.

[2]  J. Portais,et al.  Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. , 1996, Biochimie.

[3]  Julian L Griffin,et al.  Understanding mouse models of disease through metabolomics. , 2006, Current opinion in chemical biology.

[4]  Andrew N Lane,et al.  Isotopomer-based metabolomic analysis by NMR and mass spectrometry. , 2008, Methods in cell biology.

[5]  Marta Cascante,et al.  K-ras Codon-Specific Mutations Produce Distinctive Metabolic Phenotypes in Human Fibroblasts , 2005 .

[6]  K. Garber.  Energy boost: the Warburg effect returns in a new theory of cancer. , 2004, Journal of the National Cancer Institute.

[7]  C. Manetti,et al.  Metabolic profiling by 13C-NMR spectroscopy: [1,2-13C2]glucose reveals a heterogeneous metabolism in human leukemia T cells. , 2006, Biochimie.

[8]  H. Degani,et al.  Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies , 2007, International journal of cancer.

[9]  W. Mackinnon,et al.  Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. , 1997, Radiology.

[10]  M. Mcculloch,et al.  Diagnostic Accuracy of Canine Scent Detection in Early- and Late-Stage Lung and Breast Cancers , 2006, Integrative cancer therapies.

[11]  R. Scolyer,et al.  Rapid detection of metastatic melanoma in lymph nodes using proton magnetic resonance spectroscopy of fine needle aspiration biopsy specimens , 2003, Melanoma research.

[12]  Andrew N. Lane,et al.  Quantification and identification of isotopomer distributions of metabolites in crude cell extracts using 1H TOCSY , 2007, Metabolomics.

[13]  Adam L. Meadows,et al.  Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. , 2006, Metabolic engineering.

[14]  Andrew N Lane,et al.  The promise of metabolomics in cancer molecular therapeutics. , 2004, Current opinion in molecular therapeutics.

[15]  V. Raman,et al.  RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. , 2005, Cancer research.

[16]  Erin E. Carlson,et al.  Targeted profiling: quantitative analysis of 1H NMR metabolomics data. , 2006, Analytical chemistry.

[17]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[18]  David Gallego-Ortega,et al.  Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. , 2005, Cancer research.

[19]  G. Kruppa,et al.  Metabolomics applications of FT-ICR mass spectrometry. , 2005, Mass spectrometry reviews.

[20]  Oliver Fiehn,et al.  A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.

[21]  N. Serkova,et al.  Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. , 2006, Pharmacogenomics.

[22]  Laura K. Schnackenberg,et al.  Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma , 2006, Metabolomics.

[23]  John C. Lindon,et al.  NMR Spectroscopy of Biofluids , 1999 .

[24]  R. Kauppinen,et al.  Tumour metabolomics in animal models of human cancer. , 2007, Journal of proteome research.

[25]  J. Griffiths,et al.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. , 2006, Cancer research.

[26]  M Cascante,et al.  Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. , 2001, The Journal of biological chemistry.

[27]  M. O'Doherty,et al.  [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  E. Eigenbrodt,et al.  The tumor metabolome. , 2003, Anticancer research.

[29]  Andrew N. Lane,et al.  Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells , 2006, Metabolomics.

[30]  Steven Mennerick,et al.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Powis,et al.  Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. , 2001, Archives of Biochemistry and Biophysics.

[32]  M. Phillips,et al.  Variation in volatile organic compounds in the breath of normal humans. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[33]  L. Boros.  Metabolic targeted therapy of cancer: current tracer technologies and future drug design strategies in the old metabolic network , 2005, Metabolomics.

[34]  L. Boros,et al.  Detection of Resistance to Imatinib by Metabolic Profiling , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[35]  Elaine Holmes,et al.  Metabonomics: systems biology in pharmaceutical research and development. , 2004, Current opinion in molecular therapeutics.

[36]  Z. Bhujwalla,et al.  Molecular Causes of the Aberrant Choline Phospholipid Metabolism in Breast Cancer , 2004, Cancer Research.

[37]  M. Medina,et al.  Glutamine and cancer. , 2001, The Journal of nutrition.

[38]  H. Degani,et al.  Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. , 2002, Cancer research.

[39]  M. Moyer,et al.  Determination of volatile products of human colon cell line metabolism by GC/MS analysis , 2007, Metabolomics.

[40]  Andrew N Lane,et al.  Integrating Metabolomics and Transcriptomics for Probing Se Anticancer Mechanisms , 2006, Drug metabolism reviews.